XBIO - Xenetic

Xenetic Biosciences Inc reports results for the quarter ended in March - Earnings Summary

* Xenetic Biosciences Inc reported a quarterly adjusted loss of 6 cents per share for the quarter ended in March. The lone analyst forecast for the quarter was for a loss of 11 cents per share.

* Revenue rose 55.7% to $605.84 thousand from a year ago; analysts expected $410.00 thousand.

* Xenetic Biosciences Inc's reported EPS for the quarter was a loss of 6 cents.

* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

* Xenetic Biosciences Inc shares had fallen by 1.0% this quarter and gained 41.0% so far this year.

* The company reported a quarterly loss of $856.55 thousand.
* Wall Street's median 12-month price target for Xenetic Biosciences Inc is $4.00
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

By fineco
 
Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock
Oggi 18:31 - RSF
 
sono dei vostri trombato anch'io.....e vabbe
 
Sempre dentro pure io, purtroppo… l’ho tenuta per più di un anno tanto vale rimanere ancora… tra il 30% dell’investimento e zero poco mi cambia…
 
Vendere adesso non ha molto senso.... questa ha ancora epolong pending....DNase in avviamento sul quale stanno puntando molto.....il reverse a questo punto è il male minore....anzi....
 
Indietro